X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (160) 160
middle aged (93) 93
aged (81) 81
adult (79) 79
oncology (74) 74
female (73) 73
male (67) 67
hematology (64) 64
antineoplastic combined chemotherapy protocols - therapeutic use (48) 48
prognosis (47) 47
aged, 80 and over (36) 36
remission induction (35) 35
survival analysis (35) 35
treatment outcome (33) 33
cytarabine - administration & dosage (30) 30
acute disease (26) 26
adolescent (26) 26
chronic myelogenous leukemia (26) 26
antineoplastic combined chemotherapy protocols - adverse effects (24) 24
antineoplastic agents - therapeutic use (23) 23
survival rate (22) 22
therapy (21) 21
acute myeloid-leukemia (20) 20
acute lymphoblastic-leukemia (17) 17
acute myelogenous leukemia (17) 17
animals (17) 17
leukemia, myeloid - drug therapy (17) 17
chronic myeloid-leukemia (16) 16
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (16) 16
leukemia, myeloid, acute - drug therapy (16) 16
myelodysplastic syndromes - drug therapy (16) 16
drug administration schedule (15) 15
imatinib mesylate (15) 15
mice (15) 15
vidarabine - analogs & derivatives (15) 15
benzamides (14) 14
chemotherapy (14) 14
myelodysplastic syndromes (14) 14
cancer (13) 13
karyotyping (13) 13
follow-up studies (12) 12
leukemia (12) 12
leukemia, myelogenous, chronic, bcr-abl positive - pathology (12) 12
philadelphia chromosome (12) 12
salvage therapy (12) 12
antineoplastic agents - administration & dosage (11) 11
cell line (11) 11
chronic myelomonocytic leukemia (11) 11
cytarabine (11) 11
dose-response relationship, drug (11) 11
drug therapy (11) 11
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (11) 11
recurrence (11) 11
risk factors (11) 11
survival (11) 11
vidarabine - administration & dosage (11) 11
antineoplastic agents - adverse effects (10) 10
antineoplastic agents - pharmacology (10) 10
antineoplastic combined chemotherapy protocols - administration & dosage (10) 10
cells (10) 10
chronic myeloid leukemia (10) 10
cyclophosphamide - administration & dosage (10) 10
disease-free survival (10) 10
drug resistance (10) 10
index medicus (10) 10
leukemia - drug therapy (10) 10
leukemia, myeloid - metabolism (10) 10
leukemia, myeloid - pathology (10) 10
mutation (10) 10
myelodysplastic syndromes - mortality (10) 10
physiological aspects (10) 10
piperazines - pharmacology (10) 10
pyrimidines - pharmacology (10) 10
time factors (10) 10
topotecan - administration & dosage (10) 10
chromosome aberrations (9) 9
classification (9) 9
colony-forming units assay (9) 9
cytarabine - adverse effects (9) 9
hemic and lymphatic diseases (9) 9
leukemia, myeloid - genetics (9) 9
leukemia, myeloid, acute - genetics (9) 9
leukocyte count (9) 9
myelodysplastic syndrome (9) 9
phase-ii (9) 9
prognostic factors (9) 9
proportional hazards models (9) 9
trial (9) 9
tumor cells, cultured (9) 9
acute myeloid leukemia (8) 8
aml (8) 8
disease progression (8) 8
dose cytosine-arabinoside (8) 8
expression (8) 8
leukemia - pathology (8) 8
leukemia, myelomonocytic, chronic - genetics (8) 8
leukemia, myelomonocytic, chronic - pathology (8) 8
multivariate analysis (8) 8
myelodysplastic syndromes - pathology (8) 8
phase-i (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer treatment and research, ISSN 0927-3042, 2008, Volume 142, pp. 107 - 132
Journal Article
Cancer Cell, ISSN 1535-6108, 2011, Volume 20, Issue 1, pp. 11 - 24
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2005, Volume 11, Issue 13, pp. 4941 - 4947
Resistance to or intolerance of imatinib in patients with Philadelphia chromosome–positive chronic myelogenous leukemia (CML) has encouraged the development of... 
kinase inhibitor | chronic myeloid leukemia | imatinib | AMN107 | resistance | Philadelphia chromosome | CHRONIC MYELOGENOUS LEUKEMIA | CYTOGENETIC RESPONSES | PHASE | ONCOLOGY | SCID MICE | TYROSINE KINASE | ACUTE LYMPHOBLASTIC-LEUKEMIA | STI571 RESISTANCE | IMMUNODEFICIENT MOUSE MODEL | CELL-LINES | MESYLATE THERAPY | Apoptosis - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Pyrimidines - chemistry | Dose-Response Relationship, Drug | Caspases - metabolism | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Caspase 3 | Female | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Fusion Proteins, bcr-abl - chemistry | Cell Survival - drug effects | Models, Molecular | Treatment Outcome | Piperazines - therapeutic use | Pyrimidines - pharmacology | Mice, SCID | Xenograft Model Antitumor Assays - methods | Imatinib Mesylate | Piperazines - pharmacology | Blotting, Western | Animals | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Survival Analysis | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Benzamides | Cell Cycle - drug effects | Fusion Proteins, bcr-abl - metabolism
Journal Article
Journal Article
Blood, ISSN 0006-4971, 2006, Volume 108, Issue 2, pp. 419 - 425
The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics, pathologic features, and cytogenetic abnormalities. This... 
TRIAL | ERYTHROPOIETIN | MULTICENTER | THERAPY | COLONY-STIMULATING FACTOR | LENALIDOMIDE | ANEMIA | THALIDOMIDE | HEMATOLOGY | DARBEPOETIN ALPHA | MDS | Treatment Outcome | Myelodysplastic Syndromes - diagnosis | Remission Induction | Humans | Practice Guidelines as Topic
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2000, Volume 18, Issue 3, pp. 547 - 561
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 12/2004, Volume 101, Issue 12, pp. 2788 - 2801
BACKGROUND Modern intensive chemotherapy regimens have improved the prognosis for patients with adult acute lymphocytic leukemia (ALL). With these regimens,... 
acute lymphocytic leukemia (ALL) | hyperfractionated cyclophosphamide | vincristine | doxorubicin | long‐term follow‐up | and dexamethasone (Hyper‐CVAD) regimen | Acute lymphocytic leukemia (ALL) | Hyperfractionated cyclophosphamide | Long-term follow-up | And dexamethasone (Hyper-CVAD) regimen | Doxorubicin | Vincristine | MAINTENANCE CHEMOTHERAPY | COMPLETE REMISSION | STANDARD-RISK | BONE-MARROW-TRANSPLANTATION | ALLOGENEIC TRANSPLANT | CHILDHOOD | doxorubicin, and dexamethasone (Hyper-CVAD) regimen | THERAPY | ONCOLOGY | longterm follow-up | ACUTE LYMPHOBLASTIC-LEUKEMIA | CHILDRENS CANCER GROUP | GROUP-B | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Risk | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Vincristine - administration & dosage | Adult | Bone Marrow - drug effects | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Drug Administration Schedule | Remission Induction | Dexamethasone - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Central Nervous System Neoplasms - drug therapy | Doxorubicin - adverse effects | Cyclophosphamide | Care and treatment | Dexamethasone | Dosage and administration | Acute lymphocytic leukemia | Drug therapy
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 05/2008, Volume 7, Issue 5, pp. 1130 - 1139
The initial success of the first synthetic bcr-abl kinase inhibitor imatinib has been dampened by the emergence of imatinib-resistant disease in blast crisis...